EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Anemia of Chronic Disease Revisited: Hepcidin Dysregulation, Erythropoietic Failure, and Emerging Roles of SGLT2 Inhibition

Mohammed Abdulgayoom iD, Awni Alshurafa, Rasha Kaddoura iD, Abdulrahman F Al-Mashdali iD, Shehab F Mohamed iD, Mohamed A Yassin

European Journal of Haematology · 2026-08 · 117 (2) · 296-304

DOI: 10.1111/ejh.70197 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Journal of Haematology, online erschienen am 13.04.2026. Verfasst von Mohammed Abdulgayoom und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, National Center for Cancer Care and Research (NCCCR), Hamad Medical Corporation, Doha, Qatar. Hauptthemen laut MEDLINE: Hepcidins, Anemia, Sodium-Glucose Transporter 2 Inhibitors, Erythropoiesis. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Anemia of chronic disease (ACD), also referred to as anemia of inflammation, is a prevalent and clinically significant complication of chronic infection, autoimmune disease, malignancy, and chronic kidney disease. It is characterized by inflammation‐driven iron sequestration, impaired erythropoietin (EPO) production and signaling, and suppression of effective erythropoiesis. Current therapies (iron supplementation and erythropoiesis‐stimulating agents) often address downstream consequences and may be limited by hepcidin‐driven functional iron deficiency, cytokine‐mediated EPO resistance, and safety concerns in vulnerable populations. This review re‐examines ACD through an integrated framework of hepcidin dysregulation, iron sequestration, and inflammatory inhibition of the EPO axis. We then synthesize emerging evidence that sodium–glucose cotransporter 2 (SGLT2) inhibitors produce sustained increases in hemoglobin/hematocrit beyond transient hemoconcentration across cardiovascular and kidney disease trials, including in non‐diabetic populations. Mechanistic studies suggest a coordinated biologic response that may include reduced hepcidin, improved iron mobilization, physiologic augmentation of endogenous EPO, and attenuation of systemic inflammation—pathways directly relevant to ACD. We critically re‐appraise current ACD paradigms by contrasting downstream “replacement” strategies (iron and ESAs) with pathway‐level approaches (HIF‐PHIs and SGLT2 inhibition), and we outline biomarker‐guided study designs to test whether SGLT2 inhibition may act as an adjunctive physiologic modulator of iron–erythropoietic crosstalk in well‐phenotyped inflammatory anemia cohorts, while emphasizing that current evidence remains hypothesis‐generating rather than practice‐changing.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HepcidinsAnemiaSodium-Glucose Transporter 2 InhibitorsErythropoiesisHumansChronic DiseaseIronErythropoietinSodium-Glucose Transporter 2AnimalsDisease SusceptibilityBiomarkersInflammation

Stichwörter der Autor:innen

SGLT2 inhibitorsanemia of chronic diseaseerythropoiesishepcidininflammationiron metabolism

Substanzen

HepcidinsSodium-Glucose Transporter 2 InhibitorsIronErythropoietinSodium-Glucose Transporter 2Biomarkers

Autor:innen und Institutionen

  • Department of Hematology, National Center for Cancer Care and Research (NCCCR), Hamad Medical Corporation, Doha, Qatar.
  • Pharmacy Department, Heart Hospital, Hamad Medical Corporation, Doha, Qatar.

ORCID-Profile: Mohammed Abdulgayoom, Rasha Kaddoura, Abdulrahman F Al-Mashdali, Shehab F Mohamed

Zitieren

APA

Abdulgayoom, M., Alshurafa, A., Kaddoura, R., Al-Mashdali, A. F., Mohamed, S. F., & Yassin, M. A. (2026). Anemia of Chronic Disease Revisited: Hepcidin Dysregulation, Erythropoietic Failure, and Emerging Roles of SGLT2 Inhibition. European Journal of Haematology, 117(2), 296-304. https://doi.org/10.1111/ejh.70197

Vancouver

Abdulgayoom M, Alshurafa A, Kaddoura R, Al-Mashdali AF, Mohamed SF, Yassin MA. Anemia of Chronic Disease Revisited: Hepcidin Dysregulation, Erythropoietic Failure, and Emerging Roles of SGLT2 Inhibition. European Journal of Haematology. 2026;117(2):296-304. doi:10.1111/ejh.70197

BibTeX
@article{Abdulgayoom2026,
  author = {Abdulgayoom, Mohammed and Alshurafa, Awni and Kaddoura, Rasha and Al-Mashdali, Abdulrahman F and Mohamed, Shehab F and Yassin, Mohamed A},
  title = {Anemia of Chronic Disease Revisited: Hepcidin Dysregulation, Erythropoietic Failure, and Emerging Roles of SGLT2 Inhibition},
  journal = {European Journal of Haematology},
  year = {2026},
  volume = {117},
  number = {2},
  pages = {296--304},
  doi = {10.1111/ejh.70197}
}
Kostenlos starten →